(EL) EssilorLuxottica S. A. - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: PA (France) | Market Cap: 80.100m EUR | Total Return: 22.8% in 12m
Avg Turnover: 104M
Warnings
Fakeout Below Avwap Earnings
Tailwinds
No distinct edge detected
EssilorLuxottica S.A. (EL) is a vertically integrated global leader in the design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses. The company manages a vast portfolio of proprietary and licensed brands, including Ray-Ban, Oakley, and Varilux, while also producing advanced diagnostic and imaging equipment for eye care professionals. Its operations span the entire vision care value chain, from lens R&D and manufacturing to wholesale distribution and direct-to-consumer retail through physical stores and e-commerce platforms.
The eyewear industry is characterized by high barriers to entry due to the technical complexity of lens manufacturing and the necessity of extensive global distribution networks. EssilorLuxottica’s business model leverages this integration to capture margins at both the production and retail levels, serving diverse markets including independent opticians, large retail chains, and medical institutions. Investors looking for deeper fundamental insights can find further data on ValueRay.
Headquartered in Paris, the company has expanded its technological footprint through acquisitions in medical imaging and optical surfacing equipment. This diversification allows the firm to provide end-to-end solutions, ranging from vision assessment and pathology diagnosis to the final fitting of prescription eyewear.
- Global premium eyewear demand drives Ray-Ban and Oakley brand revenue growth
- Vertical integration of lens manufacturing and retail networks optimizes operating margins
- Expansion into myopia management solutions captures high-growth pediatric vision care market
- Luxury brand licensing renewals and royalties impact long-term wholesale revenue stability
- Direct-to-consumer digital transformation accelerates high-margin e-commerce sales across global markets
| Net Income: 4.67b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.99 > 1.0 |
| NWC/Revenue: -0.26% < 20% (prev -0.05%; Δ -0.22% < -1%) |
| CFO/TA 0.16 > 3% & CFO 10.2b > Net Income 4.67b |
| Net Debt (17.1b) to EBITDA (13.2b): 1.30 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (469.3m) vs 12m ago 3.56% < -2% |
| Gross Margin: 61.51% > 18% (prev 63.26%; Δ -1.75% > 0.5%) |
| Asset Turnover: 88.41% > 50% (prev 72.73%; Δ 15.68% > 0%) |
| Interest Coverage Ratio: 29.13 > 6 (EBIT TTM 6.96b / Interest Expense TTM 239.0m) |
| A: -0.00 (Total Current Assets 12.0b - Total Current Liabilities 12.2b) / Total Assets 63.9b |
| B: 0.04 (Retained Earnings 2.31b / Total Assets 63.9b) |
| C: 0.11 (EBIT TTM 6.96b / Avg Total Assets 62.2b) |
| D: 1.59 (Book Value of Equity 38.9b / Total Liabilities 24.4b) |
| Altman-Z'' = 2.53 = A |
| DSRI: 1.01 (Receivables 3.77b/2.97b, Revenue 55.0b/44.0b) |
| GMI: 1.03 (GM 63.26% / 61.51%) |
| AQI: 0.95 (AQ_t 0.67 / AQ_t-1 0.70) |
| SGI: 1.25 (Revenue 55.0b / 44.0b) |
| TATA: -0.09 (NI 4.67b - CFO 10.2b) / TA 63.9b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of June 08, 2026, the stock is trading at EUR 174.05 with a total of 608,050 shares traded.
Over the past week, the price has changed by -6.14%,
over one month by -1.73%,
over three months by -9.52% and
over the past year by +22.78%.
EssilorLuxottica S. A. has no consensus analysts rating.
P/E Trailing = 34.8798
P/E Forward = 23.0415
P/S = 2.8114
P/B = 2.0857
P/EG = 1.6375
Revenue TTM = 55.0b EUR
EBIT TTM = 6.96b EUR
EBITDA TTM = 13.2b EUR
Long Term Debt = 6.81b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.93b EUR (from shortTermDebt, last quarter)
Debt = 20.6b EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.56b
Net Debt = 17.1b EUR (calculated: Debt 20.6b - CCE 3.54b)
Enterprise Value = 97.2b EUR (80.1b + Debt 20.6b - CCE 3.54b)
Interest Coverage Ratio = 29.13 (Ebit TTM 6.96b / Interest Expense TTM 239.0m)
EV/FCF = 13.65x (Enterprise Value 97.2b / FCF TTM 7.12b)
FCF Yield = 7.33% (FCF TTM 7.12b / Enterprise Value 97.2b)
FCF Margin = 12.94% (FCF TTM 7.12b / Revenue TTM 55.0b)
Net Margin = 8.50% (Net Income TTM 4.67b / Revenue TTM 55.0b)
Gross Margin = 61.51% ((Revenue TTM 55.0b - Cost of Revenue TTM 21.2b) / Revenue TTM)
Gross Margin QoQ = 58.15% (prev 63.05%)
Tobins Q-Ratio = 1.52 (Enterprise Value 97.2b / Total Assets 63.9b)
Interest Expense / Debt = 1.16% (Interest Expense 239.0m / Debt 20.6b)
Taxrate = 23.93% (1.55b / 6.49b)
NOPAT = 5.30b (EBIT 6.96b * (1 - 23.93%))
Current Ratio = 0.99 (Total Current Assets 12.0b / Total Current Liabilities 12.2b)
Debt / Equity = 0.53 (Debt 20.6b / totalStockholderEquity, last quarter 38.9b)
Debt / EBITDA = 1.30 (Net Debt 17.1b / EBITDA 13.2b)
Debt / FCF = 2.40 (Net Debt 17.1b / FCF TTM 7.12b)
Total Stockholder Equity = 39.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.51% (Net Income 4.67b / Total Assets 63.9b)
RoE = 11.97% (Net Income TTM 4.67b / Total Stockholder Equity 39.0b)
RoCE = 15.19% (EBIT 6.96b / Capital Employed (Equity 39.0b + L.T.Debt 6.81b))
RoIC = 9.82% (NOPAT 5.30b / Invested Capital 53.9b)
WACC = 5.97% (E(80.1b)/V(101b) * Re(7.28%) + D(20.6b)/V(101b) * Rd(1.16%) * (1-Tc(0.24)))
Discount Rate = 7.28% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 2.48%
[DCF] Terminal Value 77.97% ; FCFF base≈6.25b ; Y1≈7.16b ; Y5≈10.5b
[DCF] Fair Price = 307.4 (EV 159b - Net Debt 17.1b = Equity 141b / Shares 460.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -54.48 | EPS CAGR: -0.99% | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.07 | Revenue CAGR: 4.80% | SUE: 0.09 | # QB: 0
EPS current Year (2026-12-31): EPS=7.36 | Chg30d=N/A | Revisions=-14% | GrowthEPS=+8.3% | GrowthRev=+9.0%
EPS next Year (2027-12-31): EPS=8.41 | Chg30d=N/A | Revisions=-14% | GrowthEPS=+14.3% | GrowthRev=+10.8%
[Analyst] Revisions Ratio: -14%